DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1889)

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis Kisqali and Eli Lilly’s Verzenio) are creating new dynamics in the metastatic HR+/HER2– treatment practice. In HER2+ breast cancer, emerging HER2-targeting drugs currently in development are forecasted to enter the market, while current HER2-targeting agents see their sales changing as a result of competition, label expansions, biosimilars entry and new trials leading to changes in treatment guidelines. Furthermore, the approval of AstraZeneca’s Lynparza and anticipated future entry of other PARP inhibitors and immune checkpoint inhibitors will provide more diverse treatment options, especially for triple-negative breast cancer.

Questions answered:

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as AZ’s Lynparza, or label extensions like Roche/Genentech’s Perjeta in the HER2 adjuvant setting or Eli Lilly’s Verzenio in HR first-line metastatic setting?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • December 2018
      • October 2018
      • September 2018
      • June 2018
      • March 2018
      • December 2017
      • July 2017
      • June 2017
      • March 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Breast Cancer?
        • What Factors Are Constraining the Market for Breast Cancer?
      • Segment-Specific Trends
        • Adjuvant and Neoadjuvant Market
        • First-Line Market
        • Second- and Subsequent-Line Market
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Prognostic Biomarkers
        • Patterns of Metastasis
      • Staging and Classification
        • Staging of Breast Cancer
      • Prognostic Gene Expression Signatures
        • Oncotype Dx
        • MammaPrint
        • The Quest H:I Ratio Test
      • Key Pathways and Drug Targets
        • Key Pathways and Drug Targets for Breast Cancer
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Molecular Subtype
        • Stage at Diagnosis
        • Menopausal Status
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • HER2-Targeted Agents
        • CDK4/6 Inhibitors
        • mTOR Pathway Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
        • SERDs
        • PARP Inhibitors
      • Medical Practice
        • Neoadjuvant Treatment of Stage II/III Breast Cancer
        • Adjuvant Hormone Treatment of Stage I-III Breast Cancer
        • Adjuvant Chemotherapy Treatment of Stage I-III Breast Cancer
        • Adjuvant Targeted Treatment of Stage I-III Breast Cancer
        • First-Line Hormone Treatment of Advanced/Metastatic Breast Cancer
        • First-Line Chemotherapy Treatment of Advanced/Metastatic Breast Cancer
        • First-Line Targeted Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Hormone Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Chemotherapy Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Targeted Treatment of Advanced/Metastatic Breast Cancer
        • Treatment Guidelines
        • Country-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Breast Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Breast Cancer
        • PARP Inhibitors
        • PI3K/AKT/mTOR Pathway Inhibitors
        • Immune Checkpoint Inhibitors
        • HER2/EGFR-Targeting Agents
        • Cytotoxic Agents
        • HDAC Inhibitors
        • RANKL-Targeting Agents
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Breast Cancer
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Breast Cancer Bibliography
      • Supplemental Breast Cancer Epidemiology Bibliography

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Andrianos Liavas, Ph.D; Alison Isherwood, MSc, MRes, PhD
  • is a senior business insights analyst in the oncology team at Decision Resources Group. Before joining DRG, Dr. Liavas worked as a management consultant in healthcare, designing brand and commercial strategy solutions for pharmaceutical companies on a variety of therapy areas, including oncology, immunology and diabetes. He also previously worked as a business & technology consultant at GlaxoSmithKline on digital marketing strategy design and HCP engagement. Dr. Liavas holds a in biological sciences with honours in pharmacology from the University of Edinburgh and a in clinical neuroscience from University College London, focusing on genetic therapies for treating epilepsy.

  • Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.

Purchase Report

Recent reports:
You may also be interested in: